Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $314 million, a 2% increase from Q4 2024 and a 1% increase from the previous quarter [13] - Full year 2025 total revenue was $1.185 billion, compared to $1.112 billion in 2024 [18] - Non-GAAP earnings per share for Q4 2025 was $0.40, down from $0.60 in Q4 2024 [15] - GAAP earnings per share for Q4 2025 was a loss of $0.05, compared to a profit of $0.34 in Q4 2024 [15] - Annual recurring revenue (ARR) exited Q4 2025 at $636 million, a 10% increase from the 2024 exit rate [8][17] Business Line Data and Key Metrics Changes - Product revenue for Q4 2025 was $180 million, a decrease of 1% compared to Q4 2024 [14] - Service revenue for Q4 2025 was $134 million, an increase of 8% from Q4 2024 [14] - Full year 2025 product revenue was $666 million, compared to $631 million in 2024 [19] - Full year 2025 service revenue was $519 million, compared to $482 million in 2024 [19] Market Data and Key Metrics Changes - Competitive wins included major health systems in Louisiana, Mississippi, Texas, and New England [10] - The Department of Veterans Affairs selected Omnicell's solutions for medication management across their network [11] - The company noted increasing patient volumes and improving financial performance in publicly traded health systems [11] Company Strategy and Development Direction - The company aims to transform into an end-to-end medication management platform technology company [5] - Focus on expanding market presence, scaling recurring revenue, and accelerating the technology platform [6] - Introduction of Titan XT, an automated dispensing system, is part of the strategy to enhance customer experience and operational efficiency [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the momentum coming out of 2025, driven by autonomous medication management [11] - There is potential uncertainty around regulations and tariffs, but overall hospital fundamentals remain strong [11] - The company anticipates a modest revenue contribution from Titan XT in 2026, with a focus on preparing customers for the transition [30] Other Important Information - Non-GAAP gross margin for Q4 2025 was 43.2%, down from 47.4% in Q4 2024 [14][22] - Cash and cash equivalents totaled $197 million as of December 31, 2025, down from $369 million a year earlier [15][16] - The company is investing in sales force and clinical education to capitalize on market opportunities [41][43] Q&A Session Summary Question: How should the product booking expectations be viewed in relation to the XT cycle? - Management believes the refresh cycle opportunity exceeds $2.5 billion, with a similar rollout expected over the next 8 years [36] Question: Will there be incremental investments in sales and support for the Titan cycle? - Management confirmed investments in the sales force and clinical education to enhance market engagement [41][43] Question: What feedback has been received from customers regarding the XT Extend and Titan? - Customers with aging fleets are inclined to upgrade to Titan XT, while those with XT Extend can still access cloud capabilities [47] Question: How will tariff costs impact gross margins moving forward? - Management is implementing mitigation strategies and expects some natural benefits from these efforts in 2026 [51] Question: What is the competitive landscape and how is Omnicell positioned? - The timing of the Titan XT announcement has opened more conversations with customers, enhancing competitive positioning [56]